SASPject PT1.2 is an antibiotic protein technology that offers a new approach to treat serious life-threatening bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA). RapidFACT will be used to
Discovered by Otsuka, OPA-6566 is an ophthalmic solution indicated to reduce intraocular pressure in open-angle glaucoma (OAG) or ocular hypertension patients The trial aims to evaluate the safety,
With the initiation of this trial, Abbott has paid a $10m milestone payment to Neurocrine. Neurocrine president and CEO Kevin Gorman said they are pleased that their collaboration
CompleoTRT’s delivery technology is designed to provide patients with the therapeutic effect of supplementing testosterone levels while doing so with a small amount of drug in the form
Viocare provides nutrition-based technology platforms for community, corporate and health care provided wellness programs. DSM CIO Rob van Leen said their investment in Viocare in conjunction with the
Quantum trial will evaluate interferon-free regimens of PSI-7977 400mg QD and PSI-938 300mg QD with and without ribavirin over 12 or 24 weeks in patients with HCV who
Vitamin Code formulas contain live enzymes and probiotics. Primal Defense Ultra is a probiotic formula delivered via UltraZorbe capsules and is packaged in the BioProtect Packaging System. Garden
ACE-536 is being developed as a treatment of anemia in a global collaboration with Celgene Corporation. The trial aims to evaluate the tolerability, pharmacodynamics, safety and pharmacokinetics of
The current BAY 94-9343 program is directed against the target molecule mesothelin. BAY 94-9343, a HuCAL-derived antibody-drug conjugate, showed potent, targeted anticancer activity against mesothelin- expressing tumors in
The company intends to open the 330,000 sq² facility in 2011 with a plan to employ approximately 280 employees in the first year of operation and based on
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.